Transcriptomics

Dataset Information

0

Targeting the mevalonate pathway potentiates NUAK1 inhibition-induced immunogenic cell death and antitumor immunity


ABSTRACT: The induction of immunogenic cell death (ICD) impedes tumor progression via both tumor cell-intrinsic and -extrinsic mechanisms, representing a robust therapeutic strategy. However, there remains a dearth of ICD-inducing targets. Employing kinome-wide CRISPR-Cas9 screening, we have identified NUAK1 as a potential target. The ICD-provoking effect of NUAK1 inhibition depends on the production of reactive oxygen species (ROS), consequent to the downregulation of NRF2-mediated antioxidant gene expression. Moreover, the mevalonate pathway/cholesterol biosynthesis, activated by XBP1s downstream of NUAK1 inhibition-induced endoplasmic reticulum stress, functions as negative feedback on ICD. Targeting the mevalonate pathway using HMGCR inhibitor statins amplifies NUAK1 inhibition-mediated ICD and antitumor activity, while cholesterol mitigates ICD by diminishing ROS. The combination of NUAK1 inhibitors and statins enhances the efficacy of anti-PD-1 therapy. Collectively, our study unveils the promise of blocking the mevalonate pathway in conjunction with ICD-targeted immunotherapies such as NUAK1 inhibition.

ORGANISM(S): Mus musculus

PROVIDER: GSE264513 | GEO | 2024/12/10

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2024-12-11 | GSE283933 | GEO
2015-05-19 | E-GEOD-42787 | biostudies-arrayexpress
2015-05-19 | GSE42787 | GEO
| PRJNA1196347 | ENA
| PRJNA1102878 | ENA
2018-02-26 | PXD008229 | Pride
2018-03-31 | E-MTAB-3263 | biostudies-arrayexpress
2020-02-01 | GSE129925 | GEO
2020-02-24 | GSE107998 | GEO
2022-02-25 | GSE191034 | GEO